Patient Data Shows Safe Switch from Genzyme to Shire Drug

Due to the temporary closing of Genzyme’s Allston plant last summer, MBBP client Shire’s new Gaucher Disease treatment VPRIV was fast-tracked and approved by the FDA.

Shire is now reporting data from a Phase 3 study which showed that when patients switched from Genzyme’s Cerezyme to Shire’s VPRIV, in the same dosage, several key health indicators remained the same.

For more information, please visit Shire.